Despite the RLT field going through a period of rapid growth and innovation, with the market projected to reach over $14 billion by 2032, the last FDA approved therapy occurred almost 4 years ago. Considering the increasing competition in the market there is a question at the forefront of the industries mind – how do we move beyond phase one studies?

Join the first plenary session to see how industry leaders are doing just that.